Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients

Aleman, Adolfo; Oekelen, Oliver Van; Upadhyaya, Bhaskar; Beach, Katherine F.; Zajdman, Ariel Kogan; Alshammary, Hala; Serebryakova, Kseniya; Agte, Sarita; Kappes, Katerina; Gleason, Charles; Srivastava, Komal; Almo, S.C.; Cordon‐Cardo, Carlos; Krammer, Florian; Mérad, Miriam; Jagannath, Sundar; Wajnberg, Ania; Simon, Viviana; Parekh, Samir; Andre, Dalles; Azad, A.; Banu, Radhika; Bermudez-Gonzalez, Maria; Cai, Gianna; Chari, Ajai; Cho, Han Na; Cognigni, Christian; David, Karen; Floda, Daniel; Firpo, A.; Kleiner, Giulio; Lyttle, Neko; Mendez, Wanni A.; Mulder, L.C.F.; Mendu, Rao; Oostenink, A.; Rooker, A.; Richard, Shambavi; Richter, Joshua; Rodriguez, Cesar; Rossi, Alessia; Russo, Kayla; Sanchez, Larysa; Salimbangon, A.; Saksena, Miti; Shin, A.; Sominsky, Levy A.; Verina, Daniel

doi:10.1016/j.ccell.2022.03.013

Cited by 32 publications

(51 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The kinetics of NAb decay after the second and the third BNT162b2 seem to be quite similar, although the humoral response after the first booster dose is superior than after the second vaccine shot. 7 , 21 , 22 Interestingly, we found that the median NAbs levels at 1 month after the second booster BNT162b2 are similar to those detected at 1 month following the first booster BNT162b2 in patients with MM. Another recent study has also demonstrated that the second booster shot with a mRNA-based vaccine restores the NAb levels to the high values that had been previously achieved after the first booster shot with BNT162b2 in individuals without MM.…”

Section: Discussionsupporting

confidence: 66%

Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy

Ntanasis‐Stathopoulos

Karalis

Gavriatopoulou

et al. 2022

HemaSphere

View full text Add to dashboard Cite

COVID-19 vaccination leads to a less intense humoral response in patients with multiple myeloma (MM) compared with healthy individuals, whereas the SARS-CoV-2-specific immunity fades over time. The purpose of this study was to explore the kinetics of SARS-CoV-2 neutralizing antibodies (NAbs) in patients with MM after vaccination with the BNT162b2 mRNA vaccine, focusing on their response before (B4D) and at 1 month after the fourth vaccination (M1P4D). Overall, 201 patients with a median age of 67 years were included, whereas 114 (56.7%) were men. The median NAbs levels B4D were 80.0% (±3.5%) and at M1P4D they increased to a median value of 96.1% (±3.7%). The NAb values at M1P4D were similar to those at 1 month post the third dose and superior to all previous timepoints. At M1P4D, the NAbs levels of all the treatment groups increased, apart from the anti-BCMA group. A significant increase in median NAbs values was observed for those receiving CD38-based treatment (n = 43, from 71.0% B4D to 96.0% at M1P4D) and those who did not receive CD38- or BCMA-targeted therapy (n = 137, from 89.6% B4D to 96.3% at M1P4D). Regarding the patients under BCMA-based therapy (n = 21), there was no remarkable increase in NAbs values following the second booster shot (from 3.0% B4D to 4.0% at M1P4D). In conclusion, booster vaccination with the BNT162b2 results in a substantially improved humoral response against SARS-CoV-2 in patients with MM. Anti-BCMA treatment remains an adverse predictive factor for NAbs response; thus, tailored prevention measures should be considered for this patient subgroup.

show abstract

Section: Discussionsupporting

confidence: 66%

Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy

Ntanasis‐Stathopoulos

Karalis

Gavriatopoulou

et al. 2022

HemaSphere

View full text Add to dashboard Cite

show abstract

“… 12 Therefore, additional vaccine administration might be avoided in these patients, at least in the short‐term (see comparison of the overall titres in Figure 1E,F ). In good agreement, three studies 13 , 14 , 15 have recently claimed that smaller subsets of HM patients with prior SARS‐CoV‐2 infection in their study cohorts displayed enhanced immune response compared to infection‐naïve patients. In addition, and consistent with other reports, we also show that patients treated with chemo‐free therapies during vaccination tend to exhibit lower anti‐s and NAb titres than those measured in patients under chemo‐based regimens, suggesting that the humoral response to vaccination in HM patients may be affected by continuous treatment with antineoplastic agents, chiefly BTK inhibitors, that impair innate immunity.…”

supporting

confidence: 61%

Induction of robust humoral immunity against SARS‐CoV‐2 after vaccine administration in previously infected haematological cancer patients

et al. 2022

View full text Add to dashboard Cite

“…Recently, augmented humoral and cellular response after the third dose of SARS-CoV-2 vaccination has been reported. These data highlight a suboptimal serological response against the Omicron variant, but they do not clarify the variant-dependent neutralization capacity and T cell response in detail after third-dose vaccination in patients with MM ( Aleman et al., 2022 ).…”

mentioning

confidence: 80%

Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma

et al. 2022

View full text Add to dashboard Cite

Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients

Cited by 32 publications

References 10 publications

Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy

Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy

Induction of robust humoral immunity against SARS‐CoV‐2 after vaccine administration in previously infected haematological cancer patients

Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma

Contact Info

Product

Resources

About